Andrew Mujugira

Summary

Publications

  1. pmc Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Sex Transm Infect 87:238-41. 2011
  2. pmc Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, WA, USA
    BMC Res Notes 4:64. 2011
  3. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
  4. pmc Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
    Jairam R Lingappa
    Department of Global Health, Seattle, WA, USA
    Lancet 375:824-33. 2010
  5. pmc Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
    AIDS 27:2155-60. 2013
  6. pmc Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
  7. pmc Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception
    Renee Heffron
    aDepartment of Global Health bDepartment of Medicine cDepartment of Epidemiology dPediatrics and Laboratory Medicine eDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA fCenter for Clinical Research, Kenya Medical Research Institute, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret hDepartment of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital iCenter for Microbiology, Kenya Medical Research Institute, Nairobi, Kenya jVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kDepartments of Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada The Partners PrEP Study Team is listed in the Acknowledgements
    AIDS 28:2771-6. 2014
  8. pmc Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters
    Mary S Campbell
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 207:1166-70. 2013
  9. pmc Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health, University of Washington, Seattle, Washington, USA cUniversity of Manitoba, Department of Internal Medicine, Winnipeg, Canada dCenter for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics and Gynaecology, University of Nairobi fDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret, Kenya hDepartment of Medicine, University of Washington iStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    AIDS 28:1825-30. 2014
  10. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010

Detail Information

Publications22

  1. pmc Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, USA
    Sex Transm Infect 87:238-41. 2011
    ..To compare the performance of the Focus HerpeSelect-2 enzyme immunoassay (EIA) with the gold standard herpes simplex virus (HSV) type 2 western blot, among HIV-1-uninfected men and women in east and southern Africa...
  2. pmc Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, WA, USA
    BMC Res Notes 4:64. 2011
    ..abstract:..
  3. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  4. pmc Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial
    Jairam R Lingappa
    Department of Global Health, Seattle, WA, USA
    Lancet 375:824-33. 2010
    ..Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression...
  5. pmc Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Obstetrics and Gynaecology, University of Nairobi eDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi, Kenya fDivision of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda gDivision of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland hStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA iCenters for Disease Control and Prevention, Atlanta, Georgia, USA Members of the Partners PrEP Study Team listed at end of paper
    AIDS 27:2155-60. 2013
    ..One hypothesis proposed for these divergent results is that PrEP efficacy may be reduced in populations with higher HIV-1 incidence...
  6. pmc Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial: implications for measuring adherence
    DEBORAH J DONNELL
    Department of Global Health, University of Washington, Seattle, USA
    AIDS Behav 17:632-9. 2013
    ..e., fewer pills returned than expected) and when pill counts were missing because bottles were not returned, plasma HIV-1 RNA and GUD effects were diminished, likely indicating periods of non-adherence...
  7. pmc Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception
    Renee Heffron
    aDepartment of Global Health bDepartment of Medicine cDepartment of Epidemiology dPediatrics and Laboratory Medicine eDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA fCenter for Clinical Research, Kenya Medical Research Institute, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret hDepartment of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital iCenter for Microbiology, Kenya Medical Research Institute, Nairobi, Kenya jVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA kDepartments of Medicine and Medical Microbiology, University of Manitoba, Winnipeg, Canada The Partners PrEP Study Team is listed in the Acknowledgements
    AIDS 28:2771-6. 2014
    ..To evaluate preexposure prophylaxis (PrEP) efficacy for HIV-1 prevention among women using depot medroxyprogesterone acetate (DMPA) for contraception and men whose HIV-1-infected partners use DMPA...
  8. pmc Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters
    Mary S Campbell
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 207:1166-70. 2013
    ..Our data do not support the hypothesis that higher early viral load accounts for the rapid spread of HIV-1 subtype C in southern Africa...
  9. pmc Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception
    Pamela M Murnane
    aDepartment of Epidemiology bDepartment of Global Health, University of Washington, Seattle, Washington, USA cUniversity of Manitoba, Department of Internal Medicine, Winnipeg, Canada dCenter for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics and Gynaecology, University of Nairobi fDepartment of Obstetrics and Gynaecology, Kenyatta National Hospital, Nairobi gDepartment of Reproductive Health, Moi University, Eldoret, Kenya hDepartment of Medicine, University of Washington iStatistical Center for HIV AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    AIDS 28:1825-30. 2014
    ..For women at risk of HIV-1, effective contraception and effective HIV-1 prevention are global priorities...
  10. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  11. pmc Acyclovir Prophylaxis Reduces the Incidence of Herpes Zoster Among HIV-Infected Individuals: Results of a Randomized Clinical Trial
    Ruanne V Barnabas
    Department of Global Health, University of Washington Department of Medicine, University of Washington Department of Epidemiology, University of Washington Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    J Infect Dis 213:551-5. 2016
    ..68/100 person-years, respectively), a relative decrease of 62% (hazard ratio, 0.38; 95% confidence interval, .24-.67; P < .001). Daily acyclovir prophylaxis significantly reduced herpes zoster incidence among HIV-infected persons. ..
  12. pmc Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples
    Jillian Pintye
    Department of Global Health, University of Washington, Seattle, WA, USA Department of Nursing, University of Washington, Seattle, WA, USA
    Lancet Glob Health 2:e664-71. 2014
    ..We aimed to assess whether male circumcision was associated with incident syphilis in men and in their female partners...
  13. pmc Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships
    Andrew Mujugira
    Departments of Global Health, Epidemiology, and Medicine, University of Washington, Seattle, WA Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya Department of Medicine, Makerere University, Kampala, Uganda and Kabwohe Clinical Research Centre, Kabwohe, Uganda
    J Acquir Immune Defic Syndr 66:436-42. 2014
    ..Uptake of ART among HIV-infected partners in serodiscordant partnerships is not known, which we evaluated in African HIV serodiscordant couples...
  14. pmc HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples
    Erin Kahle
    aDepartment of Epidemiology bDepartment of Global Health cDepartment of Medicine dDepartment of Pediatrics eDepartment of Microbiology fDepartment of Laboratory Medicine, University of Washington gVaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA hKenya Medical Research Institute, Kisumu, Kenya iDepartment of Medicine, Indiana University, Indianapolis, Indiana, USA jDepartment of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi, Kenya kLondon School of Hygiene and Tropical Medicine, London, UK
    AIDS 28:235-43. 2014
    ..We compared the risk of HIV-1 transmission for subtype C versus non-C subtypes (A, D, G and recombinant forms) among heterosexual African HIV-1 serodiscordant couples...
  15. pmc Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships
    Andrew Mujugira
    1 Department of Global Health, University of Washington, Seattle, Washington
    AIDS Res Hum Retroviruses 32:148-54. 2016
    ..Among those initiating ART, we sought to explore whether those same factors were associated with failure to achieve viral suppression...
  16. pmc Pre-exposure prophylaxis does not affect the fertility of HIV-1-uninfected men
    Edwin O Were
    aDepartment of Reproductive Health, Moi University, Eldoret, Kenya bDepartment of Global Health, University of Washington, Seattle, Washington, USA cCentre for Clinical Research dCentre for Microbiology Research, Kenya Medical Research Institute eDepartment of Obstetrics and Gynecology, Kenyatta National Hospital, Nairobi, Kenya fDepartment of Medicine gDepartment of Epidemiology hDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA Members of the Partners PrEP Study Team are listed in the Acknowledgements section
    AIDS 28:1977-82. 2014
    ....
  17. pmc HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention
    Deborah Donnell
    Department of Global Health University of Washington and Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research Center, Seattle, WA Departments of Global Health Medicine Epidemiology, University of Washington, Seattle, WA Departments of Pharmacology and Molecular Sciences Medicine, Johns Hopkins University, Baltimore, MD Center for Global Health, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, MA Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda Department of Obstetrics and Gynecology, University of Nairobi and Kenyatta National Hospital, Nairobi and Department of Epidemiology, Johns Hopkins University, Baltimore, MD
    J Acquir Immune Defic Syndr 66:340-8. 2014
    ..Antiretroviral pre-exposure prophylaxis (PrEP) is a novel HIV prevention strategy for which adherence is a known determinant of efficacy. Blood concentrations of PrEP medications are one objective marker of adherence...
  18. pmc Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention
    Andrew Mujugira
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e25828. 2011
    ..We describe the trial design and characteristics of the study cohort...
  19. pmc High Rate of β-Globin DNA Detection Validates Self-Sampling in Herpes Simplex Virus Shedding Studies
    Andrew Mujugira
    From the Departments of Global Health, Epidemiology, Laboratory Medicine, and Medicine, University of Washington, Seattle, WA and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
    Sex Transm Dis 42:705-9. 2015
    ..We investigated whether a host gene, β-globin, can be used to confirm adequacy of self-collected mucosal and skin genital specimens in studies of genital herpes simplex virus type 2 (HSV-2) infection...
  20. pmc Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study
    Jairam R Lingappa
    Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 4:e5272. 2009
    ..We describe the baseline characteristics of this cohort...
  21. pmc Regional differences in prevalence of HIV-1 discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention trial
    Jairam R Lingappa
    University of Washington, Department of Medicine, Seattle, Washington, USA
    PLoS ONE 3:e1411. 2008
    ..Substantial regional differences exist in HIV-1 prevalence in Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported...